Business Wire

Toranomon-Azabudai Project and Toranomon Hills Area Project in Tokyo Precertified under LEED ND and WELL

Share

Mori Building Co., Ltd., Japan’s leading urban landscape developer, announced today that major redevelopments the company is undertaking in Tokyo have been precertified under the prestigious LEED (Leadership in Energy and Environmental Design) and WELL (WELL Building Standard) rating systems that respectively certify environmentally friendly and efficient green buildings and people’s wellbeing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210523005028/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Toranomon-Azabudai Project (Credit: DBOX for Mori Building Co.)

The Toranomon-Azabudai Project and Toranomon Hills Area Project both received top Platinum-level LEED ND (Neighborhood Development, v.4) precertifications. The Toranomon-Azabudai and Toranomon Hills Area projects are respectively the first and second projects in Tokyo to be precertified Platinum in the ND category. LEED is the most widely used green-building rating system that evaluates and certifies buildings and cities worldwide for environmental performance in terms of water and energy efficiency, indoor environments and sustainable materials. LEED is managed by the U.S. Green Building Council (USGBC).

The A District of the Toranomon-Azabudai Project and the A-1 District of Toranomon Hills Station Tower (tentative name) received WELL (Core,v.2 Pilot) precertifications; the former is the world’s largest precertified property and the latter is Japan’s second largest precertified property. WELL is the world’s first performance-based system for measuring, certifying and monitoring features of the built environment that impact human health and wellbeing through air, water, nourishment, light, fitness, comfort and mind. WELL is also managed by the USGBC. Once completed, both projects are expected to obtain WELL Platinum certifications.

Mahesh Ramanujam, president and CEO of USGBC and also Green Business Certification Inc., which provides third-party credentialing and verification under the LEED, WELL and GRESB systems, said:
“Mori Building’s sustainability efforts and its LEED Platinum achievement are fine examples of how organizations can transform their communities by lowering carbon emissions, creating healthier environments and work towards a zero-carbon future.Throughawarding advanced examples such as Mori building, we aspire to demonstrate how better buildings, better communities and better cities can help raise the living standard for all.”

Mori Building, based on its philosophy of “Create cities, nurture cities,” is committed to realizing a sustainable global society through the harmonious coexistence of cities and nature, low-carbon cities and truly enhanced health.

LEED ND Platinum Precertifications

The Toranomon-Azabudai Project was highly evaluated as a complex with diverse urban functions, a walkable urban center built with a central square, and also for its renewable-energy power supply. Toranomon Hills Station Tower was favorably assessed for its integration of public transportation, including the new subway station, and high-level energy efficiency.

In both projects, Mori Building’s emphasis on urban development in partnership with local landowners earned high marks in the ND category. Toranomon-Azabudai Project became Tokyo’s first project to earn a Platinum level in the ND category and Toranomon Hills Area Project quickly followed as the second such project. It is globally rare for complexes in urban business areas to receive Platinum-level precertification.

WELL Platinum Precertifications

The Toranomon-Azabudai Project’s A District and Toranomon Hills Station Tower (tentative name)’s A-1 District were highly evaluated as advanced urban redevelopments following the concept of each project, offering central squares with substantial greenery, indoor environments with excellent air quality through use of air conditioners equipped with high-performance filters, cafes serving healthful meals and layouts featuring central squares and elevated decks to promote exercise. Once completed, both projects are expected to obtain Platinum certifications.

The A District of the Toranomon-Azabudai Project is the world’s largest precertified property and the A-1 District of Toranomon Hills Station Tower (tentative name) is Japan’s second largest precertified property.

Reference: Toranomon-Azabudai Project
https://www.mori.co.jp/en/img/article/210524_2.pdf

About Toranomon-Azabudai Project
https://www.mori.co.jp/en/projects/toranomon_azabudai/

Toranomon-Azabudai Project Image Movie
https://www.youtube.com/watch?v=5akVE7tWOto&feature=emb_logo

Reference: Toranomon Hills Area project
https://www.mori.co.jp/en/img/article/210524_3.pdf

About Toranomon Hills Area project
https://www.mori.co.jp/en/projects/toranomonhills_area/

Press releases:
https://www.mori.co.jp/en/img/article/190822.pdf
https://www.mori.co.jp/en/img/article/200610_1.pdf
https://www.mori.co.jp/en/img/article/210218_1.pdf

About Mori Building

Mori Building is an innovative urban developer based in Tokyo. The company is committed to maximizing the magnetic power of cities by creating and nurturing safe, sustainable and cosmopolitan urban centers based on its unique Vertical Garden City concept of high-rise centers for business, education, leisure and residence. The concept is applied in the company’s many leading-edge projects, including ARK Hills, Roppongi Hills and Toranomon Hills in Tokyo and the Shanghai World Financial Center. Mori Building is also engaged in real estate leasing, project management and consultation. Please visit www.mori.co.jp/en

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

International Media Inquiries
Saori Asano
Public Relations, Mori Building Co., Ltd.
Tel +81 (0)3 6406 6606
Fax +81 (0)3 6406 9306
E-mail koho@mori.co.jp

Weber Shandwick Japan
Reina Matsushita (tel: +81 (0)80 2375 0295)
Mayuko Harada (tel: +81 (0)90 9006 4968)
Masashi Nonaka (tel: +81 (0)80 1037 7879)
E-mail moribldg@webershandwick.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye